Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds

Max Gelman

Senior Editor

A little more than two years after first going public, Crinetics Pharmaceuticals is nearing the Phase III trial for its lead program. That candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Cri­net­ic­s' acromegaly drug hits pri­ma­ry PhII end­point, but in­vestors can't make up their minds

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds